Literature DB >> 19737558

Adenosine mediates transforming growth factor-beta 1 release in kidney glomeruli of diabetic rats.

H Roa1, C Gajardo, E Troncoso, V Fuentealba, C Escudero, A Yáñez, L Sobrevia, M Pastor-Anglada, C Quezada, R San Martin.   

Abstract

Up regulation of the transforming growth factor-beta 1 (TGF-beta1) axis has been recognized as a pathogenic event for progression of glomerulosclerosis in diabetic nephropathy. We demonstrate that glomeruli isolated from diabetic rats accumulate up to sixfold more extracellular adenosine than normal rats. Both decreased nucleoside uptake activity by the equilibrative nucleoside transporter 1 and increased AMP hydrolysis contribute to raise extracellular adenosine. Ex vivo assays indicate that activation of the low affinity adenosine A2B receptor subtype (A2BAR) mediates TGF-beta1 release from glomeruli of diabetic rats, a pathogenic event that could support progression of glomerulopathy when the bioavailability of adenosine is increased.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19737558     DOI: 10.1016/j.febslet.2009.09.003

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  17 in total

1.  SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.

Authors:  Xiaoxin X Wang; Jonathan Levi; Yuhuan Luo; Komuraiah Myakala; Michal Herman-Edelstein; Liru Qiu; Dong Wang; Yingqiong Peng; Almut Grenz; Scott Lucia; Evgenia Dobrinskikh; Vivette D D'Agati; Hermann Koepsell; Jeffrey B Kopp; Avi Z Rosenberg; Moshe Levi
Journal:  J Biol Chem       Date:  2017-02-14       Impact factor: 5.157

Review 2.  Adenosine signalling in diabetes mellitus--pathophysiology and therapeutic considerations.

Authors:  Luca Antonioli; Corrado Blandizzi; Balázs Csóka; Pál Pacher; György Haskó
Journal:  Nat Rev Endocrinol       Date:  2015-02-17       Impact factor: 43.330

Review 3.  Alteration of purinergic signaling in diabetes: Focus on vascular function.

Authors:  Rui Zhou; Xitong Dang; Randy S Sprague; S Jamal Mustafa; Zhichao Zhou
Journal:  J Mol Cell Cardiol       Date:  2020-02-11       Impact factor: 5.000

4.  High plasma adenosine levels in overweight/obese pregnant women.

Authors:  Priscila Badillo; Paola Salgado; Patricia Bravo; Katherine Guevara; Jesenia Acurio; Maria Angelica Gonzalez; Carlos Oyarzun; Rody San Martin; Carlos Escudero
Journal:  Purinergic Signal       Date:  2017-07-18       Impact factor: 3.765

Review 5.  CD39-adenosinergic axis in renal pathophysiology and therapeutics.

Authors:  Bellamkonda K Kishore; Simon C Robson; Karen M Dwyer
Journal:  Purinergic Signal       Date:  2018-01-13       Impact factor: 3.765

Review 6.  Purinergic signalling and diabetes.

Authors:  Geoffrey Burnstock; Ivana Novak
Journal:  Purinergic Signal       Date:  2013-04-03       Impact factor: 3.765

Review 7.  Complexity of diabetic nephropathy pathogenesis and design of investigations.

Authors:  Majid Tavafi
Journal:  J Renal Inj Prev       Date:  2013-06-01

8.  Deficient Insulin-mediated Upregulation of the Equilibrative Nucleoside Transporter 2 Contributes to Chronically Increased Adenosine in Diabetic Glomerulopathy.

Authors:  Sebastián Alarcón; Wallys Garrido; Génesis Vega; Claudio Cappelli; Raibel Suárez; Carlos Oyarzún; Claudia Quezada; Rody San Martín
Journal:  Sci Rep       Date:  2017-08-25       Impact factor: 4.379

9.  Activation of adenosine receptors improves renal antioxidant status in diabetic Wistar but not SHR rats.

Authors:  Daniela Patinha; Joana Afonso; Teresa Sousa; Manuela Morato; António Albino-Teixeira
Journal:  Ups J Med Sci       Date:  2013-11-06       Impact factor: 2.384

10.  Reduced Adenosine Uptake and Its Contribution to Signaling that Mediates Profibrotic Activation in Renal Tubular Epithelial Cells: Implication in Diabetic Nephropathy.

Authors:  Catalina Kretschmar; Carlos Oyarzún; Cristopher Villablanca; Catherinne Jaramillo; Sebastián Alarcón; Gustavo Perez; Montserrat M Díaz-Encarnación; Marçal Pastor-Anglada; Wallys Garrido; Claudia Quezada; Rody San Martín
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.